ESR1 and triple-negative breast carcinoma: Given the fact that the expression of miR-206 can be repressed by ERα (Adams et al., 2007), both JIMT-1 and BT549 that were derived from ER- or triple-negative breast cancer patients (Tanner et al., 2004; Grigoriadis et al., 2012; Tian and Zhang, 2018) should have high expression level of miR-206.